Proactive Investors - Run By Investors For Investors

Rhinomed takes its nasal breathing product into the Taiwanese market

“Mute” is an over-the-counter product to enable snorers to breathe more easily.
Rhinomed takes its nasal breathing product into the Taiwanese market
The product is designed to fit the natural anatomy of the nose

Rhinomed Ltd (ASX:RNO) has signed a distribution agreement with Brojaw Inc., to begin distributing its snoring and nasal breathing product Mute into the Taiwanese market.

The company’s shares were last trading circa 8% higher intra-day, at $0.205.

Mute is an over-the-counter product to enable snorers to breathe more easily through their nose and keep their mouth closed during sleep. In turn, this reduces vibration in the airways that causes snoring.

The product is designed to fit the natural anatomy of the nose and it is adjustable so the user can control the level of dilation and airflow.

The new non-exclusive agreement will see Brojaw distribute Mute to ear, nose and throat (ENT) clinics, sleep doctors, sleep centres, medical centres and sleep clinics in Taiwan.

This will then be followed by distribution into drug stores / pharmacies. An initial purchase order has been received.

This agreement follows the recent approval of Mute by the Taiwanese Food and Drug Administration (TFDA) as a class 1 medical device.

In July, Rhinomed received purchase orders from the U.S. pharmacy giant Walgreens for Mute to be sold in circa 4,300 pharmacy/drugstores throughout the U.S.

This 5 fold increase in U.S. distribution has occurred 12 months after the start of the initial trial that began in 107 Duane Reade stores and 891 Walgreens stores in May 2016.

View full RNO profile View Profile

Rhinomed Ltd Timeline

September 16 2015

Related Articles

lupus poster
January 18 2018
The last of the 200 patients has had their final assessment and the data is now being processed and analysed
newspaper with word cancer magnified
January 15 2018
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use